

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 18, 2025
PDL Changes Effective Date: April 1, 2025



The following changes will be made to the Preferred Drug List (PDL), effective April 1, 2025, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Select Contraceptive Products (Oral Contraceptives)	Femlyv ODT (ethinyl estradiol and norethindrone acetate)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Androgenic Agents	Undecatrex (testosterone undecanoate)
Angiotensin Modulators (ARB Combinations)	sacubitril-valsartan
Anticonvulsants (Adjuvants)	oxcarbazepine ER
Antiparkinson's Agents (Injectable)	Vyalev (foscarbidopa/foslevodopa)
Antipsychotics, Injectable (Atypicals)	Erzofri (paliperidone palmitate)
Antipsychotics, Oral	Cobenfy (xanomeline/trospium)
Antipsychotics, Oral	Opipza (aripiprazole)
Atopic Dermatitis	Ebglyss (lebrikizumab-lbkz)
Bronchodilators, Beta Agonist (Inhalation Solution)	formoterol fumarate nebulizer solution (NDCs 70644-0215-30, 70644-0215-60)
Calcium Channel Blockers (Short Acting)	nimodipine solution
Cytokine & CAM Antagonists	Nemluvio (nemolizumab-ilto)
Cytokine & CAM Antagonists	Tremfya (guselkumab) pen injector, vial
Cytokine & CAM Antagonists	Yuflyma CF (adalimumab-aaty) 40 mg/0.4 mL autoinjector
Factor Deficiency Products (Other Hemophilia Products)	Hympavzi (marstacimab-hncq)
Hypoglycemics (DPP4s and Combinations)	Zitumev (sitagliptin/metformin)
Hypoglycemics (DPP4s and Combinations)	Zitumev XR (sitagliptin/metformin)
Hypoglycemics (Incretin Mimetics/Enhancers)	exenatide
Miscellaneous Brand/Generic (Epinephrine)	Neffy (epinephrine)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 18, 2025
PDL Changes Effective Date: April 1, 2025



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Multiple Sclerosis Agents	Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)
Muscular Dystrophy Agents	Duvyzat (givinostat)
NSAIDs (Non-Selective)	Dolobid (diflunisal)
Opiate Dependence Treatments (Dependence)	lofexidine
Parathyroid Agents	Yorvipath (palopegteriparatide)
Stimulants and Related Agents (Non-Stimulants)	Onyda XR (clonidine) oral suspension